Red Queen Bio

The firm's core mission is based on the concept of "defensive co-scaling," which aims to ensure that biological defenses advance at the same rate as AI capabilities. Red Queen Bio works with frontier AI labs to map potential biothreats and preemptively build medical countermeasures. Its pipeline utilizes advanced AI models, lab automation, and reinforcement learning, coupled with on-demand biologics manufacturing, to create a scalable defense system. As a Public Benefit Corporation, its governance structure prioritizes its mission over individual partnerships.

In November 2025, Red Queen Bio launched with a $15 million seed funding round led by OpenAI. Other investors include Cerberus Ventures, Fifty Years, and Halcyon Futures. The company's business model explores frameworks similar to catastrophic risk insurance and involves direct collaboration with AI labs, biopharma companies, and governments to create a sustainable financial model for biosecurity that is not solely reliant on government funding.